Researchers at University Medical Center Utrecht have uncovered a previously underappreciated mechanism that helps immune ...
Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney Diseases
Eli Lilly has expanded its genetic medicines pipeline and capabilities, agreeing to partner with Ascidian Therapeutics to develop RNA exon editors intended to treat inherited kidney diseases, through ...
Eli Lilly and Ascidian Therapeutics said Wednesday that they’re teaming up in a research collaboration to find new medicines for genetically driven kidney diseases, the latest foray into genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results